Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability
Publication date
2013
Authors
Crunelle, C.L.
van der Giessen, E.
Schulz, S.
Vanderschuren, L.J.M.J.
de Bruin, K.
van den Brink, W.
Booij, J.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Econometric and Statistical Methods: General, Geneeskunde (GENK), Geneeskunde(GENK), Medical sciences, Bescherming en bevordering van de menselijke gezondheid, Taverne
Citation
Crunelle, C L, van der Giessen, E, Schulz, S, Vanderschuren, L J M J, de Bruin, K, van den Brink, W & Booij, J 2013, 'Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability', Addiction Biology, vol. 18, no. 6, pp. 908-911. https://doi.org/10.1111/j.1369-1600.2011.00369.x